Nominations to the Network Portfolio Advisory Group

Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 72, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Vaxxinact H5, Avian influenza virus, subtype H5, haemagglutinin (recombinant), Status: Authorised

EMA workshop: Non-clinical data for regulatory decision-making on the efficacy of medical countermeasures, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 24 November 2025, 09:00 (CET) to 25 November 2025, 16:00 (CET)

Report - Industry stakeholders' feedback on engagement and communication activities

Human medicines European public assessment report (EPAR): Voraxaze, glucarpidase, Date of authorisation: 11/01/2022, Revision: 3, Status: Authorised

Highlight report - Combination Products Operational Group (COMBO) - Medical Devices stream

Highlight report - Combination Products Operational Group (COMBO) - In Vitro Diagnostics stream

Webinar for stakeholder engagement on the new draft guideline on general considerations for patient preference studies (ICH E22), Online, Broadcast, from 6 February 2026, 13:30 (CET) to 6 February 2026, 17:00 (CET)

EMA press briefing on human medicines in 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 15 January 2026, 14:00 (CET) to 15 January 2026, 14:45 (CET)